NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
William G. Wierda(The University of Texas MD Anderson Cancer Center), Hema Sundar(National Comprehensive Cancer Network), Tanya Siddiqi(City Of Hope National Medical Center), Brian T. Hill(Cleveland Clinic), Claudio A. Mosse(Breast Cancer Research Foundation), Asher Chanan‐Khan(WinnMed), Randall S. Davis(University of Colorado Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Steven Coutré(Georgetown University), Jennifer R. Brown(Dana-Farber Cancer Institute), Deborah M. Stephens(University of North Carolina at Chapel Hill), Thomas J. Kipps(University of California San Diego), Danielle M. Brander(Duke University), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Paul Kaesberg(UC Davis Comprehensive Cancer Center), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Herbert Eradat(University of Colorado Cancer Center), Nadia Khan(Fox Chase Cancer Center), Sameh Gaballa(Johns Hopkins Hospital), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Armin Ghobadi(Washington University in St. Louis), Muhammad Saad Hamid(Piedmont Cancer Institute), J Christine Ye(University of Michigan), Anthony Mato(Memorial Sloan Kettering Cancer Center), Greg Bociek(Susan Thompson Buffett Foundation), Mary A. Dwyer(National Comprehensive Cancer Network), Manali Kamdar(University of Colorado Cancer Center), S Bilgrami(Yale Cancer Center), Jeremy S. Abramson(Massachusetts General Hospital)
Cited by 84
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k